Michael N Dworzak

List of Publications by Year
in descending order

174	9,434	36303	42399
papers	citations	51 h-index	92 g-index

176	176	176	8788
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood, 2012, 120, 3187-3205.	1.4	451
2	The MLL recombinome of acute leukemias in 2013. Leukemia, 2013, 27, 2165-2176.	7.2	393
3	Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood, 2009, 114, 2489-2496.	1.4	383
4	Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study. Blood, 2011, 118, 2077-2084.	1.4	370
5	Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents. Blood, 2016, 127, 1387-1397.	1.4	304
6	Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18â€“20 September 2008. Leukemia, 2010, 24, 521-535.	7.2	302
7	Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood, 2002, 99, 1952-1958.	1.4	294
8	Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia. Journal of Clinical Oncology, 2015, 33, 2949-2962.	1.6	277
9	Risk of Relapse of Childhood Acute Lymphoblastic Leukemia Is Predicted By Flow Cytometric Measurement of Residual Disease on Day 15 Bone Marrow. Journal of Clinical Oncology, 2009, 27, 5168-5174.	1.6	247
10	Early Deaths and Treatment-Related Mortality in Children Undergoing Therapy for Acute Myeloid Leukemia: Analysis of the Multicenter Clinical Trials AML-BFM 93 and AML-BFM 98. Journal of Clinical Oncology, 2004, 22, 4384-4393.	1.6	230
11	Treatment and prognostic impact of transient leukemia in neonates with Down syndrome. Blood, 2008, 111, 2991-2998.	1.4	228
12	Characterization of Rare, Dormant, and Therapy-Resistant Cells in Acute Lymphoblastic Leukemia. Cancer Cell, 2016, 30, 849-862.	16.8	215
13	Improved Outcome in Pediatric Relapsed Acute Myeloid Leukemia: Results of a Randomized Trial on Liposomal Daunorubicin by the International BFM Study Group. Journal of Clinical Oncology, 2013, 31, 599-607.	1.6	197
14	Prognostic Impact of Specific Chromosomal Aberrations in a Large Group of Pediatric Patients With Acute Myeloid Leukemia Treated Uniformly According to Trial AML-BFM 98. Journal of Clinical Oncology, 2010, 28, 2682-2689.	1.6	190
15	Less Toxicity by Optimizing Chemotherapy, but Not by Addition of Granulocyte Colony-Stimulating Factor in Children and Adolescents With Acute Myeloid Leukemia: Results of AML-BFM 98. Journal of Clinical Oncology, 2006, 24, 4499-4506.	1.6	173
16	High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood, 2011, 117, 3409-3420.	1.4	168
17	Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012. Leukemia, 2018, 32, 2167-2177.	7.2	155
18	Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 2004. Blood, 2013, 122, 37-43.	1.4	151

#	Article	IF	Citations
19	CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy. Blood, 2008, 112, 3982-3988.	1.4	134
20	Residual Disease Monitoring in Childhood Acute Myeloid Leukemia by Multiparameter Flow Cytometry: The MRD-AML-BFM Study Group. Journal of Clinical Oncology, 2006, 24, 3686-3692.	1.6	132
21	Consequent and intensified relapse therapy improved survival in pediatric AML: results of relapse treatment in 379 patients of three consecutive AML-BFM trials. Leukemia, 2010, 24, 1422-1428.	7.2	124
22	Minimal Residual Disease Values Discriminate Between Low and High Relapse Risk in Children With B-Cell Precursor Acute Lymphoblastic Leukemia and an Intrachromosomal Amplification of Chromosome 21: The Austrian and German Acute Lymphoblastic Leukemia Berlin-Frankfurt-MÃ¼nster (ALL-BFM) Trials. Journal of Clinical Oncology, 2008, 26, 3046-3050.	1.6	108
23	<scp>AIEOP</scp>â€<scp>BFM</scp> Consensus Guidelines 2016 for Flow Cytometric Immunophenotyping of Pediatric Acute Lymphoblastic Leukemia. Cytometry Part B - Clinical Cytometry, 2018, 94, 82-93.	1.5	96
24	Time point-dependent concordance of flow cytometry and real-time quantitative polymerase chain reaction for minimal residual disease detection in childhood acute lymphoblastic leukemia. Haematologica, 2012, 97, 1582-1593.	3.5	95
25	Acute leukaemias of ambiguous lineage in children: characterization, prognosis and therapy recommendations. British Journal of Haematology, 2010, 149, 84-92.	2.5	92
26	Changes in cytogenetics and molecular genetics in acute myeloid leukemia from childhood to adult age groups. Cancer, 2016, 122, 3821-3830.	4.1	92
27	RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia. Nature Communications, 2017, 8, 2126.	12.8	91
28	Pediatric acute myeloid leukemia with t(8;16)(p11;p13), a distinct clinical and biological entity: a collaborative study by the International-Berlin-Frankfurt-MÃ¼nster AML-study group. Blood, 2013, 122, 2704-2713.	1.4	86
29	Clinical evolution, genetic landscape and trajectories of clonal hematopoiesis in SAMD9/SAMD9L syndromes. Nature Medicine, 2021, 27, 1806-1817.	30.7	79
30	The role of matched sibling donor allogeneic stem cell transplantation in pediatric high-risk acute myeloid leukemia: results from the AML-BFM 98 study. Haematologica, 2012, 97, 21-29.	3.5	78
31	Structure of the human TNF receptor 1 (p60) gene (TNRF1) and localization to chromosome 12p13. Genomics, 1992, 13, 219-224.	2.9	76
32	Treatment with caspofungin in immunocompromised paediatric patients: a multicentre survey. Journal of Antimicrobial Chemotherapy, 2006, 57, 527-535.	3.0	75
33	Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study. British Journal of Haematology, 2010, 148, 768-776.	2.5	75
34	Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia: Results of the CA180-018 Phase I Dose-Escalation Study of the Innovative Therapies for Children With Cancer Consortium. Journal of Clinical Oncology, 2013, 31, 2460-2468.	1.6	75
35	Clinical Impact of Additional Cytogenetic Aberrations, cKIT and RAS Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-MÃ¼nster Study Group. Journal of Clinical Oncology, 2015, 33, 4247-4258.	1.6	75
36	Induction death and treatment-related mortality in first remission of children with acute lymphoblastic leukemia: a population-based analysis of the Austrian Berlin-Frankfurt-MÃ¼nster study group. Leukemia, 2009, 23, 1264-1269.	7.2	71

#	Article	IF	Citations
37	International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia. Blood, 2018, 132, 264-276.	1.4	70
38	Heterogeneous cytogenetic subgroups and outcomes in childhood acute megakaryoblastic leukemia: a retrospective international study. Blood, 2015, 126, 1575-1584.	1.4	69
39	Diagnosis of invasive fungal infections by a real-time panfungal PCR assay in immunocompromised pediatric patients. Leukemia, 2010, 24, 2032-2038.	7.2	67
40	Spliceosomal gene aberrations are rare, coexist with oncogenic mutations, and are unlikely to exert a driver effect in childhood MDS and JMML. Blood, 2012, 119, e96-e99.	1.4	65
41	Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia. Haematologica, 2015, 100, 935-944.	3.5	64
42	Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trial. Blood, 2017, 129, 3314-3321.	1.4	64
43	Granulocyte Colony-Stimulating Factor (G-CSF) Treatment of Childhood Acute Myeloid Leukemias That Overexpress the Differentiation-Defective G-CSF Receptor Isoform IV Is Associated With a Higher Incidence of Relapse. Journal of Clinical Oncology, 2010, 28, 2591-2597.	1.6	62
44	Outcome of children with primary resistant or relapsed non-Hodgkin lymphoma and mature B-cell leukemia after intensive first-line treatment: A population-based analysis of the Austrian cooperative study group. Pediatric Blood and Cancer, 2005, 44, 70-76.	1.5	61
45	Longâ€term outcome of initially homogenously treated and relapsed childhood acute lymphoblastic leukaemia in Austria â€“ A populationâ€based report of the Austrian Berlinâ€Frankfurtâ€MÃ¼nster (BFM) Study Group. British Journal of Haematology, 2009, 144, 559-570.	2.5	61
46	Favorable outcome in infants with AML after intensive first- and second-line treatment: an AML-BFM study group report. Leukemia, 2012, 26, 654-661.	7.2	60
47	Bridging to transplant with azacitidine in juvenile myelomonocytic leukemia: a retrospective analysis of the EWOG-MDS study group. Blood, 2015, 125, 2311-2313.	1.4	60
48	Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international study. Blood, 2011, 117, 7102-7111.	1.4	58
49	Monitoring treatment response of childhood precursor B-cell acute lymphoblastic leukemia in the AIEOP-BFM-ALL 2000 protocol with multiparameter flow cytometry: predictive impact of early blast reduction on the remission status after induction. Leukemia, 2009, 23, 528-534.	7.2	56
50	Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16). Blood, 2011, 118, 5409-5415.	1.4	56
51	Incidence and outcome of TCF3-PBX1-positive acute lymphoblastic leukemia in Austrian children. Haematologica, 2007, 92, 1561-1564.	3.5	55
52	Improved outcome of pediatric patients with acute megakaryoblastic leukemia in the AML-BFM 04 trial. Annals of Hematology, 2015, 94, 1327-1336.	1.8	54
53	Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia. Blood, 2007, 109, 936-943.	1.4	52
54	Favourable outcome of patients with childhood acute promyelocytic leukaemia after treatment with reduced cumulative anthracycline doses. British Journal of Haematology, 2010, 149, 399-409.	2.5	52

#	Article	IF	Citations
55	Expression of CD58 in normal, regenerating and leukemic bone marrow B cells: implications for the detection of minimal residual disease in acute lymphocytic leukemia. Haematologica, 2003, 88, 1245-52.	3.5	52
56	Prednisone induces immunophenotypic modulation of CD10 and CD34 in nonapoptotic Bâ€cell precursor acute lymphoblastic leukemia cells. Cytometry Part B - Clinical Cytometry, 2008, 74B, 150-155.	1.5	51
57	Silencing of ETV6/RUNX1 abrogates PI3K/AKT/mTOR signaling and impairs reconstitution of leukemia in xenografts. Leukemia, 2012, 26, 927-933.	7.2	50
58	CD99 (MIC2) expression in paediatric B-lineage leukaemia/lymphoma reflects maturation-associated patterns of normal B-lymphopoiesis. British Journal of Haematology, 1999, 105, 690-695.	2.5	49
59	Modulation of antigen expression in Bâ€cell precursor acute lymphoblastic leukemia during induction therapy is partly transient: Evidence for a drugâ€induced regulatory phenomenon. Results of the AIEOPâ€BFMâ€ALLâ€FLOWâ€MRDâ€Study Group. Cytometry Part B - Clinical Cytometry, 2010, 78B, 147-153.	1.5	46
60	Prognostic impact of t(16;21)(p11;q22) and t(16;21)(q24;q22) in pediatric AML: a retrospective study by the I-BFM Study Group. Blood, 2018, 132, 1584-1592.	1.4	45
61	CD2-positive B-cell precursor acute lymphoblastic leukemia with an early switch to the monocytic lineage. Leukemia, 2014, 28, 609-620.	7.2	43
62	Criteria for evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemia. Haematologica, 2015, 100, 17-22.	3.5	43
63	The prognostic significance of early treatment response in pediatric relapsed acute myeloid leukemia: results of the international study Relapsed AML 2001/01. Haematologica, 2014, 99, 1472-1478.	3.5	42
64	CD371 cell surface expression: a unique feature of DUX4-rearranged acute lymphoblastic leukemia. Haematologica, 2019, 104, e352-e355.	3.5	42
65	Mixed Lineage Leukemiaâ€“Rearranged Childhood Pro-B and CD10-Negative Pre-B Acute Lymphoblastic Leukemia Constitute a Distinct Clinical Entity. Clinical Cancer Research, 2006, 12, 2988-2994.	7.0	40
66	Prognostic discrimination based on the EUTOS long-term survival score within the International Registry for Chronic Myeloid Leukemia in children and adolescents. Haematologica, 2017, 102, 1704-1708.	3.5	40
67	Automated Flow Cytometric MRD Assessment in Childhood Acute Bâ€•Lymphoblastic Leukemia Using Supervised Machine Learning. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2019, 95, 966-975.	1.5	40
68	Skin-associated lymphocytes in the peripheral blood of patients with atopic dermatitis: Signs of subset expansion and stimulation. Journal of Allergy and Clinical Immunology, 1999, 103, 901-906.	2.9	39
69	Bone marrow assessment in Langerhans cell histiocytosis. Pediatric Blood and Cancer, 2007, 49, 694-698.	1.5	39
70	Detection and monitoring of normal and leukemic cell populations with hierarchical clustering of flow cytometry data. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2012, 81A, 25-34.	1.5	39
71	Bone marrow immunophenotyping by flow cytometry in refractory cytopenia of childhood. Haematologica, 2015, 100, 315-323.	3.5	38
72	Gemtuzumab ozogamicin in children with relapsed or refractory acute myeloid leukemia: a report by Berlin-Frankfurt-MÃ¼nster study group. Haematologica, 2019, 104, 120-127.	3.5	38

#	Article	IF	Citations
73	Synonymous GATA2 mutations result in selective loss of mutated RNA and are common in patients with GATA2 deficiency. Leukemia, 2020, 34, 2673-2687.	7.2	38
74	All-trans retinoic acid and arsenic trioxide resistance of acute promyelocytic leukemia with the variant STAT5B-RARA fusion gene. Leukemia, 2013, 27, 1606-1610.	7.2	37
75	Outcome of Children and Adolescents With a Second or Third Relapse of Acute Lymphoblastic Leukemia (ALL). Journal of Pediatric Hematology/Oncology, 2013, 35, e200-e204.	0.6	37
76	Comparison of horse and rabbit antithymocyte globulin in immunosuppressive therapy for refractory cytopenia of childhood. Haematologica, 2014, 99, 656-663.	3.5	36
77	Direct and Indirect Targets of the E2A-PBX1 Leukemia-Specific Fusion Protein. PLoS ONE, 2014, 9, e87602.	2.5	34
78	RASA4undergoes DNA hypermethylation in resistant juvenile myelomonocytic leukemia. Epigenetics, 2014, 9, 1252-1260.	2.7	34
79	First experience of the AMLâ€Berlinâ€Frankfurtâ€MÃ¼nster group in pediatric patients with standardâ€risk acute promyelocytic leukemia treated with arsenic trioxide and allâ€trans retinoid acid. Pediatric Blood and Cancer, 2017, 64, e26461.	1.5	32
80	Survival Following Relapse in Children with Acute Myeloid Leukemia: A Report from AML-BFM and COG. Cancers, 2021, 13, 2336.	3.7	30
81	Mediastinal mass in childhood T-cell acute lymphoblastic leukemia: Significance and therapy response. Medical and Pediatric Oncology, 2002, 39, 558-565.	1.0	29
82	Fine tuning of surface CRLF2 expression and its associated signaling profile in childhood B-cell precursor acute lymphoblastic leukemia. Haematologica, 2015, 100, e229-e232.	3.5	29
83	Exchange Transfusion and Leukapheresis in Pediatric Patients with AML With High Risk of Early Death by Bleeding and Leukostasis. Pediatric Blood and Cancer, 2016, 63, 640-645.	1.5	28
84	Death induction by CD99 ligation in TEL/AML1-positive acute lymphoblastic leukemia and normal B cell precursors. Journal of Leukocyte Biology, 2010, 88, 405-412.	3.3	27
85	Flow-Cytometric Monitoring of Minimal Residual Disease in Pediatric Patients With Acute Myeloid Leukemia: Recent Advances and Future Strategies. Frontiers in Pediatrics, 2019, 7, 412.	1.9	27
86	CD11b is a therapy resistanceâ€“ and minimal residual diseaseâ€“specific marker in precursor B-cell acute lymphoblastic leukemia. Blood, 2010, 115, 3763-3771.	1.4	26
87	Flow Cytometric Detection of Minimal Residual Disease in Acute Lymphoblastic Leukemia. Leukemia and Lymphoma, 2003, 44, 1445-1455.	1.3	25
88	CNS irradiation in pediatric acute myeloid leukemia: Equal results by 12 or 18 Gy in studies AMLâ€BFM98 and 2004. Pediatric Blood and Cancer, 2011, 57, 986-992.	1.5	25
89	Additional cytogenetic abnormalities and variant t(9;22) at the diagnosis of childhood chronic myeloid leukemia: The experience of the <scp>I</scp>nternational <scp>R</scp>egistry for <scp>C</scp>hronic <scp>M</scp>yeloid <scp>L</scp>eukemia in <scp>C</scp>hildren and <scp>A</scp>dolescents. Cancer, 2017, 123, 3609-3616.	4.1	25
90	Compliance with anti-infective preventive measures: A multicentre survey among paediatric oncology patients. European Journal of Cancer, 2008, 44, 1861-1865.	2.8	24

#	Article	IF	Citations
91	Thiamine-responsive megaloblastic anemia (TRMA) in an Austrian boy with compound heterozygous SLC19A2 mutations. European Journal of Pediatrics, 2012, 171, 1711-1715.	2.7	24
92	Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study. Haematologica, 2018, 103, 1484-1492.	3.5	24
93	Hematopoietic stem cell transplantation in children and adolescents with GATA2-related myelodysplastic syndrome. Bone Marrow Transplantation, 2021, 56, 2732-2741.	2.4	24
94	An Extensive Quality Control and Quality Assurance (QC/QA) Program Significantly Improves Inter-Laboratory Concordance Rates of Flow-Cytometric Minimal Residual Disease Assessment in Acute Lymphoblastic Leukemia: An I-BFM-FLOW-Network Report. Cancers, 2021, 13, 6148.	3.7	24
95	The role of surgery in the treatment of pediatric B-cell non-Hodgkin's lymphoma. Journal of Pediatric Surgery, 2002, 37, 1470-1475.	1.6	23
96	Age-Dependent Presentation and Clinical Course of 1465 Patients Aged 0 to Less than 18 Years with Ovarian or Testicular Germ Cell Tumors; Data of the MAKEI 96 Protocol Revisited in the Light of Prenatal Germ Cell Biology. Cancers, 2020, 12, 611.	3.7	23
97	The inferior prognosis of adolescents with acute lymphoblastic leukaemia (<scp>ALL</scp>) is caused by a higher rate of treatmentâ€related mortality and not an increased relapse rate â€“ a populationâ€based analysis of 25Âyears of the <scp>A</scp>ustrian <scp>ALLâ€BFM</scp> (Berlinâ€Frankfurtâ€MÃ¼nster) Study Group. British Journal of Haematology, 2013, 161, 556-565.	2.5	22
98	Screening for NUP98 rearrangements in hematopoietic malignancies by fluorescence in situ hybridization. Haematologica, 2005, 90, 746-52.	3.5	22
99	Blast cell deficiency of CD11a as a marker of acute megakaryoblastic leukemia and transient myeloproliferative disease in children with and without Down syndrome. Cytometry Part B - Clinical Cytometry, 2013, 84, 370-378.	1.5	20
100	Prognostic relevance of TLX3 (HOX11L2) expression in childhood Tâ€cell acute lymphoblastic leukaemia treated with Berlinâ€“Frankfurtâ€“MÃ¼nster (BFM) protocols containing early and late reâ€intensification elements. British Journal of Haematology, 2010, 148, 293-300.	2.5	19
101	MEF2C-dysregulated pediatric T-cell acute lymphoblastic leukemia is associated withCDKN1Bdeletions and a poor response to glucocorticoid therapy. Leukemia and Lymphoma, 2017, 58, 2895-2904.	1.3	19
102	Prognostic relevance of dic(9;20)(p11;q13) in childhood Bâ€cell precursor acute lymphoblastic leukaemia treated with Berlinâ€Frankfurtâ€MÃ¼nster (BFM) protocols containing an intensive induction and postâ€induction consolidation therapy. British Journal of Haematology, 2010, 149, 93-100.	2.5	18
103	Antibiotic prophylaxis with teicoplanin on alternate days reduces rate of viridans sepsis and febrile neutropenia in pediatric patients with acute myeloid leukemia. Annals of Hematology, 2017, 96, 99-106.	1.8	18
104	Flowâ€cytometric minimal residual disease monitoring in blood predicts relapse risk in pediatric Bâ€cell precursor acute lymphoblastic leukemia in trial AIEOPâ€BFMâ€ALL 2000. Pediatric Blood and Cancer, 2019, 66, e27590.	1.5	18
105	Prevalence and Clinical Course of Viral Upper Respiratory Tract Infections in Immunocompromised Pediatric Patients With Malignancies or After Hematopoietic Stem Cell Transplantation. Journal of Pediatric Hematology/Oncology, 2012, 34, 442-449.	0.6	17
106	Clustering of cell populations in flow cytometry data using a combination of Gaussian mixtures. Pattern Recognition, 2016, 60, 1029-1040.	8.1	15
107	Characteristics and outcome in patients with central nervous system involvement treated in European pediatric acute myeloid leukemia study groups. Pediatric Blood and Cancer, 2017, 64, e26664.	1.5	14
108	Asparagine and aspartic acid concentrations in bone marrow versus peripheral blood during Berlinâ€“Frankfurtâ€“MÃ¼nster-based induction therapy for childhood acute lymphoblastic leukemia. Leukemia and Lymphoma, 2012, 53, 1682-1687.	1.3	12

#	Article	IF	Citations
109	Targeted mutation screening of 292 candidate genes in 38 children with inborn haematological cytopenias efficiently identifies novel diseaseâ€causing mutations. British Journal of Haematology, 2018, 182, 251-258.	2.5	12
110	Association of unbalanced translocation der(1;7) with germline GATA2 mutations. Blood, 2021, 138, 2441-2445.	1.4	12
111	High hyperdiploid acute lymphoblastic leukemia (ALL)â€"A 25â€year populationâ€based survey of the Austrian ALLâ€BFM (Berlinâ€Frankfurtâ€MÃ¼nster) Study Group. Pediatric Blood and Cancer, 2017, 64, e26327.	1.5	11
112	Outcome of two patients with bilateral nephroblastomatosis/Wilms tumour treated with an add-on 13-cis retinoic acid therapy â€“ Case report. Pediatric Hematology and Oncology, 2018, 35, 218-224.	0.8	11
113	Characteristics and outcome of acute myeloid leukemia with uncommon retinoic acid receptor-alpha (RARA) fusion variants. Blood Cancer Journal, 2021, 11, 167.	6.2	11
114	Acute monocytic leukaemia originating from MLLâ€MLLT3â€positive preâ€B cells. British Journal of Haematology, 2010, 150, 621-623.	2.5	10
115	Flow diagnostics essential code: A simple and brief format for the summary of leukemia phenotyping. , 2014, 86, 288-291.		10
116	Rothia mucilaginosa bacteremia: A 10â€year experience of a pediatric tertiary care cancer center. Pediatric Blood and Cancer, 2019, 66, e27691.	1.5	10
117	Second Relapse of Pediatric Patients with Acute Myeloid Leukemia: A Report on Current Treatment Strategies and Outcome of the AML-BFM Study Group. Cancers, 2021, 13, 789.	3.7	10
118	Cytochemically Myeloperoxidase Positive Childhood Acute Leukemia With Lymphoblastic Morphology Treated as Lymphoblastic Leukemia. Journal of Pediatric Hematology/Oncology, 2010, 32, e4-e7.	0.6	9
119	Clonal Mutational Landscape of Childhood Myelodysplastic Syndromes. Blood, 2015, 126, 1662-1662.	1.4	9
120	Molecular characterization and clinical impact of t(11;15)(q23;q14-15) MLL-CASC5 rearrangement. Haematologica, 2014, 99, e11-e13.	3.5	8
121	UMAP Based Anomaly Detection for Minimal Residual Disease Quantification within Acute Myeloid Leukemia. Cancers, 2022, 14, 898.	3.7	8
122	Nodular pulmonary lesions in children after autologous stem cell transplantation: a source of misinterpretation. British Journal of Haematology, 2008, 140, 429-432.	2.5	7
123	Abnormal promoter DNA methylation in juvenile myelomonocytic leukemia is not caused by mutation in DNMT3A. Blood, 2011, 118, 4490-4491.	1.4	7
124	Phosphoâ€Profiling Linking Biology and Clinics in Pediatric Acute Myeloid Leukemia. HemaSphere, 2020, 4, e312.	2.7	7
125	Management of children and adolescents with gray zone lymphoma: A case series. Pediatric Blood and Cancer, 2020, 67, e28206.	1.5	7
126	Unexpected High Frequency of GATA2 Mutations in Children with Non-Familial MDS and Monosomy 7. Blood, 2012, 120, 1699-1699.	1.4	7

#	Article	IF	Citations
127	Chronic stress induces CD99, suppresses autophagy, and affects spontaneous adipogenesis in human bone marrow stromal cells. Stem Cell Research and Therapy, 2017, 8, 83.	5.5	6
128	Phase I doseâ€escalation study of volasertib in pediatric patients with acute leukemia or advanced solid tumors. Pediatric Blood and Cancer, 2019, 66, e27900.	1.5	6
129	Features and outcome of chronic myeloid leukemia at very young age: Data from the International Pediatric Chronic Myeloid Leukemia Registry. Pediatric Blood and Cancer, 2021, 68, e28706.	1.5	6
130	Impact of a Risk-Adapted Treatment Approach in Pediatric AML: A Report of the AML-BFM Registry 2012. Blood, 2019, 134, 293-293.	1.4	6
131	Treatment results of childhood acute lymphoblastic leukemia in Austria--a report of 20 years' experience. Wiener Klinische Wochenschrift, 2002, 114, 148-57.	1.9	6
132	Automated identification of cell populations in flow cytometry data with transformers. Computers in Biology and Medicine, 2022, 144, 105314.	7.0	6
133	Recurrently affected genes in juvenile myelomonocytic leukaemia. British Journal of Haematology, 2018, 182, 135-138.	2.5	5
134	The hematopoietic stem cell marker VNN2 is associated with chemoresistance in pediatric B-cell precursor ALL. Blood Advances, 2020, 4, 4052-4064.	5.2	5
135	Prognostic significance of chromosomal abnormalities at relapse in children with relapsed acute myeloid leukemia: A retrospective cohort study of the Relapsed AML 2001/01 Study. Pediatric Blood and Cancer, 2022, 69, e29341.	1.5	5
136	A Novel Fusion Gene NDEL1-Pdgfrb in a Patient with JMML with a New Variant of TKI-Resistant Mutation in the Kinase Domain of PDGFRI². Blood, 2014, 124, 613-613.	1.4	5
137	Development of treatment and clinical results in childhood AML in Austria (1993â€“2013). Memo - Magazine of European Medical Oncology, 2014, 7, 63-74.	0.5	4
138	WGAN Latent Space Embeddings for Blast Identification in Childhood Acute Myeloid Leukaemia. , 2018, , .		4
139	Recommendations for Diagnosis and Treatment of Children with Transient Abnormal Myelopoiesis (TAM) and Myeloid Leukemia in Down Syndrome (ML-DS). Klinische Padiatrie, 2021, 233, 267-277.	0.6	4
140	JMML Revisited: Role Und Outcome of Hematopoietic Stem Cell Transplantation in Subtypes of Juvenile Myelomonocytic Leukemia (JMML). Blood, 2012, 120, 955-955.	1.4	4
141	Acute Leukemias of Ambiguous Lineage; Study on 247 Pediatric Patients. Blood, 2015, 126, 252-252.	1.4	4
142	An R307H substitution in GATA1 that prevents Ser310 phosphorylation causes severe fetal anemia. Blood Advances, 2022, 6, 4330-4334.	5.2	4
143	Adolescents and young adults with acute lymphoblastic leukemia and acute myeloid leukemia. Memo - Magazine of European Medical Oncology, 2018, 11, 47-53.	0.5	3
144	Time Point-Dependent Concordance of Flow Cytometry and RQ-PCR in the MRD Detection in Childhood ALL: The Experience of the AIEOP-BFM- ALL MRD Study Group. Blood, 2008, 112, 700-700.	1.4	3

#	Article	IF	Citations
145	High Frequency of GATA1 Mutations in Childhood Non-Down Syndrome Acute Megakaryoblastic Leukemia. Blood, 2012, 120, 888-888.	1.4	3
146	Impact of Somatic Mutations on the Outcome of Children and Adolescents with Therapy-Related Myelodysplastic Syndrome. Blood, 2016, 128, 3162-3162.	1.4	3
147	Guideline for management of non-Down syndrome neonates with a myeloproliferative disease on behalf of the I-BFM AML Study Group and EWOG-MDS. Haematologica, 2022, 107, 759-764.	3.5	3
148	Cure and care for children and adolescents with acute myeloid leukemia in Middle and Eastern European countries: part II. Memo - Magazine of European Medical Oncology, 2014, 7, 3-5.	0.5	2
149	Expression Patterns of Coagulation Factor XIII Subunit A on Leukemic Lymphoblasts Correlate with Clinical Outcome and Genetic Subtypes in Childhood B-cell Progenitor Acute Lymphoblastic Leukemia. Cancers, 2020, 12, 2264.	3.7	2
150	The variable biological signature of refractory cytopenia of childhood (RCC), a retrospective EWOG-MDS study. Leukemia Research, 2021, 108, 106652.	0.8	2
151	Distribution and Outcome According to Cytogenetics in 502 Paediatric AML Patients Treated in Study AML-BFM 98.. Blood, 2008, 112, 1510-1510.	1.4	2
152	In need of special care: adolescent and young adult patients with cancer. Memo - Magazine of European Medical Oncology, 2018, 11, 5-6.	0.5	1
153	Presence of viremia during febrile neutropenic episodes in patients undergoing chemotherapy for malignant neoplasms. American Journal of Hematology, 2021, 96, 719-726.	4.1	1
154	Diagnosis and management of acute appendicitis in 21 pediatric hematology and oncology patients at a tertiary care cancer center. Scientific Reports, 2021, 11, 12170.	3.3	1
155	A Clinical Tool for Automated Flow Cytometry Based on Machine Learning Methods. Lecture Notes in Computer Science, 2017, , 537-548.	1.3	1
156	Outcome of (Novel) Subgroups in 1257 Pediatric Patients with KMT2A-Rearranged Acute Myeloid Leukemia (AML) and the Significance of Minimal Residual Disease (MRD) Status: A Retrospective Study By the I-BFM-SG. Blood, 2020, 136, 26-27.	1.4	1
157	Treatment Response and Outcome in Childhood t(1;19)/TCF3-PBX1 Positive Acute Lymphoblastic Leukemia: A Report from the Austrian BFM Group.. Blood, 2005, 106, 1458-1458.	1.4	1
158	Preventive CNS Irradiation with 12 Gy Compared to 18 Gy: Results of Studies AML-BFM 98 and 2004.. Blood, 2009, 114, 483-483.	1.4	1
159	Safety and Pharmacokinetics Of Clofarabine In Combination With High-Dose Cytarabine and Liposomal Daunorubicin In Pediatric AML: Results Of a Phase 1 Combination Study By The ITCC Consortium. Blood, 2013, 122, 2693-2693.	1.4	1
160	Clofarabine in Combination with High-Dose Cytarabine and Liposomal Daunorubicin in Pediatric AML: Results of a Phase 1B Combination Study By the ITCC Consortium. Blood, 2014, 124, 989-989.	1.4	1
161	Validation of MRD Quantification By Flow Cytometry for Pediatric BCP ALL Relapsed Patients Treated on the Intreall Protocol. Blood, 2015, 126, 1414-1414.	1.4	1
162	Failures and Successes in Pediatric Patients with Acute Myeloid Leukemia with First Relapse: A Large International Report on Current Treatment Strategies and Outcome. Blood, 2020, 136, 6-7.	1.4	1

#	Article	IF	Citations
163	Relapsed acute lymphoblastic leukaemia after allogeneic stem cell transplantation: a therapeutic dilemma challenging the armamentarium of immunotherapies currently available (case reports). Therapeutic Advances in Hematology, 2022, 13, 204062072210994.	2.5	1
164	Case Report: Refractory Cytopenia With a Switch From a Transient Monosomy 7 to a Disease-Ameliorating del(20q) in a NHEJ1-Deficient Long-term Survivor. Frontiers in Immunology, 0, 13, .	4.8	1
165	Pediatric oncology 2.0â€"shaping the future with precision. Memo - Magazine of European Medical Oncology, 2021, 14, 218-219.	0.5	0
166	Minimal Residual Disease Monitoring by Four Color Flow Cytometry before Second Induction Is an Independent Prognostic Factor in Childhood Acute Myeloid Leukemia - AML-BFM MRD Study Group.. Blood, 2005, 106, 671-671.	1.4	0
167	Integrin Alpha M Chain Expression at Diagnosis Is Inversely Correlated with Cytoreduction Rate and Is Consistently Up-Regulated during Therapy in Acute Lymphoblastic Leukemia (ALL). Blood, 2008, 112, 2526-2526.	1.4	0
168	Pediatric Acute Myeloid Leukemia with t(8;16)(p11;p13): A Distinct Clinical and Biological Entity. Results of a Collaborative Study by the International Berlin-Frankfurt-Mulˆnster AML Study Group.. Blood, 2012, 120, 2516-2516.	1.4	0
169	Clinical Impact of Additional Cytogenetic Aberrations, cKIT- and RAS Mutations and Other Factors in Pediatric t(8;21)-AML. Blood, 2014, 124, 481-481.	1.4	0
170	Pediatric Acute Megakaryoblastic Leukemia without Down Syndrome: A Retrospective Study by the International Berlin-Frankfurt-Munster Study Group (I-BFMSG). Blood, 2014, 124, 3670-3670.	1.4	0
171	Bone Marrow Immunophenotyping By Flow Cytometry in Refractory Cytopenia of Childhood. Blood, 2014, 124, 1916-1916.	1.4	0
172	Second Relapse of Pediatric Patients with Acute Myeloid Leukemia: A Report on Current Treatment Strategies and Outcome of the AML-BFM Study Group. Blood, 2020, 136, 24-24.	1.4	0
173	Second malignant neoplasms after treatment of 1487 children and adolescents with acute lymphoblastic leukemiaâ€"A populationâ€based analysis of the Austrian ALLâ€BFM Study Group. EJHaem, 0, , .	1.0	0
174	Incidence and Risk Factors of Venous Thromboembolism in Childhood Acute Lymphoblastic Leukaemia â€“ a Population-Based Analysis of the Austrian Berlin-Frankfurt-MÃ¼nster (BFM) Study Group. Pediatric Hematology and Oncology, 0, , 1-11.	0.8	0